A Phase I study of imatinib mesylate in combination with temozolomide in patients with malignant glioma.
Latest Information Update: 30 Mar 2013
Price :
$35 *
At a glance
- Drugs Imatinib (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Adverse reactions
- 21 Sep 2006 New trial record.